𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tiagabine for the Treatment of Anxiety

✍ Scribed by Daniel Crane

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
48 KB
Volume
18
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Tiagabine for social anxiety disorder
Tiagabine for social anxiety disorder
✍ Boadie W. Dunlop; Laszlo Papp; Steven J. Garlow; Paul S. Weiss; Bettina T. Knigh πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 94 KB

## Abstract Tiagabine, a selective gamma‐aminobutyric acid (GABA) reuptake inhibitor was evaluated for the treatment of patients with social anxiety disorder (SAD). Adults with SAD received open‐label tiagabine 4–16 mg per day for 12 weeks. Intent‐to‐treat data are available for 54 patients with im

Therapeutic advances: Paroxetine for the
Therapeutic advances: Paroxetine for the treatment of social anxiety disorder
✍ R. Bruce Lydiard; Julio Bobes πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 2 views

## Data from early studies of selective serotonin reuptake inhibitors have shown that these agents are effective in the treatment of social anxiety disorder (social phobia). This review highlights the outcomes of three large clinical trials of paroxetine in patients with social anxiety disorder. In

The efficacy of nefazodone augmentation
The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder
✍ Fletcher B. Taylor; Maureen R. Prather πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 1 views

Depression that fails to respond to multiple antidepressant trials, particularly when accompanied by anxiety, constitutes a difficult treatment challenge. Those with anxious depression may be less likely to respond to treatment than their cohorts without anxiety. Anxiety symptoms also predict a high